文献速递湿疹皮炎与荨麻疹

局部雷帕霉素与他米松软膏治疗口腔糜烂型扁平苔藓的随机双盲对照研究

Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double-blind, controlled study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-04-07

本研究为随机双盲对照试验,比较局部雷帕霉素溶液(1 mg/mL)与0.05%他米松软膏治疗口腔糜烂型扁平苔藓(OELP)的疗效与安全性。治疗3个月后,他米松组临床缓解率为39.4%,雷帕霉素组为27.3%,差异无统计学意义。他米松组在早期缓解及疼痛改善方面更优,超强效局部糖皮质激素仍应作为OELP的一线治疗。

要点

  • 局部雷帕霉素在3个月临床缓解率上未优于他米松软膏。
  • 他米松组在1、2个月缓解率及3个月疼痛改善方面更优。
  • 雷帕霉素组不良事件发生率43.6%,他米松组27.8%。

核心结论

  • 局部雷帕霉素对OELP的疗效未优于0.05%他米松软膏,超强效局部糖皮质激素仍应作为一线治疗。

研究设计与样本

  • 随机双盲对照试验,4年间共随机76例患者,75例接受治疗(雷帕霉素组39例,他米松组36例)。
  • 治疗方案为0.05%他米松软膏(Orabase®基质)或局部雷帕霉素溶液(1 mg/mL),每日两次,治疗3个月,随后观察3个月。

主要发现

  • 治疗3个月时,他米松组39.4%的患者和雷帕霉素组27.3%的患者达到临床缓解(OR 0.68,95%CI [0.24; 1.89];P=0.46)。
  • 治疗1个月和2个月后的缓解率、3个月后疼痛减轻及进食影响改善,他米松组均高于雷帕霉素组。
  • 两组口腔糜烂复发率相似。
  • 不良事件发生率:雷帕霉素组43.6%(主要为烧灼感、味觉障碍),他米松组27.8%(主要为口腔念珠菌感染)。

临床怎么用

  • 对于OELP,超强效局部糖皮质激素(如0.05%他米松软膏)仍应作为一线治疗。
  • 局部雷帕霉素可作为替代选择,但需权衡其较高的不良事件风险。

局限性

  • 研究受限于招募不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although superpotent topical corticosteroids are the first-line treatment for oral erosive lichen planus (OELP), topical rapamycin was found efficient in a previous case series. OBJECTIVES: To compare the efficacy and safety of topical rapamycin and betamethasone dipropionate ointment for OELP in a randomized, double-blind trial. METHODS: Patients were randomized to receive treatment with betamethasone dipropionate ointment 0.05% in Orabase® or topical rapamycin solution (1 mg/mL) on lesions twice daily for 3 months, followed by 3 months of observation. The primary outcome was clinical remission after 3 months of treatment. Secondary outcomes were clinical remission after 1 and 2 months, reduced oral pain and reduced impact on food intake after 3 months, clinical recurrence after treatment withdrawal, and adverse events. RESULTS: During a 4-year period, 76 patients were randomized and 75 received treatment (rapamycin, n = 39; betamethasone, n = 36). At 3 months, 39.4% of patients with betamethasone and 27.3% with rapamycin showed clinical remission (odds ratio 0.68, 95% CI [0.24; 1.89]; P = 0.46). Rates of remission after 1 and 2 months, reduction in pain and impact on food intake after 3 months, were higher with betamethasone than rapamycin. Recurrence of oral erosions was similar between groups. Adverse events occurred in 43.6% of patients with rapamycin (mostly burning sensation, impaired taste) and 27.8% with betamethasone (mostly oral candidiasis). CONCLUSION: Although the study was limited by insufficient recruitment, we did not find any superiority of topical rapamycin over betamethasone dipropionate ointment for OELP. Given the rapid remission and pain improvement in the betamethasone group, it appears that superpotent topical corticosteroids should remain the first-line treatment for OELP.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Samimi M, Le Gouge A, Boralevi F, et al. Topical rapamycin versus betamethasone dipropionate ointment for treating oral erosive lichen planus: a randomized, double-blind, controlled study. J Eur Acad Dermatol Venereol. 2020. PMID: 32128907. doi:10.1111/jdv.16324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。